Blurbs

Abbott Labs (ABT) Receives a Buy from UBS

In a report released today, John Sourbeer from UBS maintained a Buy rating on Abbott Labs (ABTResearch Report), with a price target of $128.00. The company’s shares closed last Wednesday at $108.81.

According to TipRanks.com, Sourbeer is ranked #7087 out of 7949 analysts.

Abbott Labs has an analyst consensus of Moderate Buy, with a price target consensus of $121.15, a 10.8% upside from current levels. In a report issued on July 12, J.P. Morgan also maintained a Buy rating on the stock with a $125.00 price target.

See the top stocks recommended by analysts >>

Abbott Labs’ market cap is currently $191B and has a P/E ratio of 22.74.

Based on the recent corporate insider activity of 187 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Read More on ABT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos